Meditation + AF Education for Atrial Fibrillation
(MEND-AF2 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether mindfulness meditation, combined with education about atrial fibrillation (AF) and weekly phone calls, can reduce symptoms and anxiety in people with paroxysmal atrial fibrillation (a type of irregular heartbeat). Participants will be divided into groups to test various combinations of meditation, education, and phone support. This trial suits those who have recently experienced AF symptoms and are comfortable with phone-based guidance and meditation practices at home. As an unphased trial, it offers a unique opportunity to explore innovative approaches to managing AF symptoms.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research shows that mindfulness meditation is generally safe. Studies have found that mindfulness-based stress reduction, a type of meditation, is well-tolerated and used for stress, depression, and anxiety. This suggests that the meditation practices in the trial should be safe for participants. Additionally, mindfulness meditation is widely practiced with few reports of negative effects. Based on this evidence, the meditation treatment in this trial is expected to be safe for prospective participants.12345
Why are researchers excited about this trial?
Unlike traditional treatments for atrial fibrillation, which often focus on medication or invasive procedures, this approach incorporates mindfulness meditation and educational modules. Researchers are excited about these treatments because they emphasize a holistic, non-invasive strategy that could improve patients' quality of life by reducing stress and potentially stabilizing heart rhythms naturally. This method involves daily meditation practice and educational support, offering a fresh perspective by addressing mental wellness alongside physical health. Additionally, regular phone calls ensure personalized support, making it a unique blend of self-care and professional guidance.
What evidence suggests that this trial's treatments could be effective for atrial fibrillation?
Studies have shown that mindfulness meditation can help people with atrial fibrillation (AF) by reducing stress, improving quality of life, and possibly lowering the frequency of AF episodes. In this trial, some participants will engage in mindfulness meditation, which research suggests may be more effective than standard care in reducing AF symptoms and enhancing daily well-being. Mindfulness meditation has also successfully helped heart patients manage anxiety and other symptoms. Overall, mindfulness meditation appears to be a promising way to improve life for those with AF.12678
Who Is on the Research Team?
Linda Ottoboni, PhD
Principal Investigator
Clinician and research scientist
Are You a Good Fit for This Trial?
This trial is for adults with Paroxysmal Atrial Fibrillation (PAF) who've had symptoms in the last 6 months. Participants must be able to engage in weekly phone calls, attend two video/phone sessions six weeks apart, and understand English. Those with severe heart failure, short life expectancy, recent hospitalization for other illnesses, prior mindfulness practice or cognitive issues cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive mindfulness meditation, AF education, and weekly phone visits for symptom management
Follow-up
Participants are monitored for changes in AF symptom burden, anxiety, and quality of life
What Are the Treatments Tested in This Trial?
Interventions
- AF Education
- Meditation
- Phone Calls
Meditation is already approved in United States, European Union for the following indications:
- Chronic Low Back Pain
- Chronic Pain Management
- Stress Reduction
Find a Clinic Near You
Who Is Running the Clinical Trial?
Stanford University
Lead Sponsor